Post-Approval U.S. Experience With Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation

Journal of the American College of Cardiology

Volumn 69, Issue 3, 2017, Pages 253-261

  Reddy, Vivek Y ^a   Gibson, Douglas N ^b   Kar, Saibal ^c   O'Neill, William ^d   Doshi, Shephal K ^e   Horton, Rodney P ^f   Buchbinder, Maurice ^g   Gordon, Nicole T ^h   Holmes, David R ⁱ  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b SCRIPPS CLINIC   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d HENRY FORD HOSPITAL   (United States)

^e SAINT JOHN'S HEALTH CENTER   (United States)

^f Texas Cardiac Arrhythmia Institute   (United States)

^g Foundation for Cardiovascular Medicine   (United States)

^h BOSTON SCIENTIFIC CORPORATION   (United States)

ⁱ MAYO CLINIC   (United States)

Author keywords

atrial fibrillation; complications; left atrial appendage closure; stroke; Watchman

Indexed keywords

ARTICLE; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; DEVICE APPROVAL; DEVICE EMBOLIZATION; DEVICE SAFETY; HEART TAMPONADE; HUMAN; LEFT ATRIAL APPENDAGE CLOSURE DEVICE; MAJOR CLINICAL STUDY; OPERATION DURATION; PERICARDIAL EFFUSION; SURGICAL MORTALITY; UNITED STATES; COMPLICATION; DEVICES; HEART ATRIUM APPENDAGE; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATION; STROKE; TREATMENT OUTCOME;

ATRIAL APPENDAGE; ATRIAL FIBRILLATION; EQUIPMENT AND SUPPLIES; HUMANS; POSTOPERATIVE COMPLICATIONS; STROKE; TREATMENT OUTCOME; UNITED STATES;

EID: 85009990084     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.10.010     Document Type: Article

References (22)

1. 1 U.S. Food and Drug Administration. WATCHMAN LAA Closure Technology–P130013. 2015. Available at: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm440621.htm. Accessed October 1, 2016.
2. 2 Holmes, D.R., Reddy, V.Y., Turi, Z.G., et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 374 (2009), 534–542.
3. 3 Reddy, V.Y., Doshi, S.K., Sievert, H., et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-year follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) trial. Circulation 127 (2013), 720–729.
4. 4 Reddy, V.Y., Sievert, H., Halperin, J., et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA 312 (2014), 1988–1998.
5. 5 Holmes, D.R., Kar, S., Price, M.J., et al. Prospective randomized evaluation of the Watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol 64 (2014), 1–12.
6. 6 Holmes, D.R. Jr., Doshi, S.K., Kar, S., et al. Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis. J Am Coll Cardiol 65 (2015), 2614–2623.
7. 7 CMS Releases National Coverage Determination for Watchman and Other LAA Devices. February 10, 2016. Available at: http://www.cardiovascularbusiness.com/topics/coronary-intervention-surgery/cms-releases-national-coverage-determination-watchman-and-other-laa-devices. Accessed March 23, 2016.
8. 8 NCDR LAAO Registry. Available at: http://cvquality.acc.org/NCDR-Home/Registries/Hospital-Registries.aspx. Accessed March 23, 2016.
9. 9 Fountain, R.B., Holmes, D.R. Jr., Chandrasekaran, K., et al. The PROTECT AF (WATCHMAN left atrial appendage system for embolic PROTECTion in patients with atrial fibrillation) trial. Am Heart J 151 (2006), 956–961.
10. 10 Reddy, V.Y., Holmes, D.R., Doshi, S.K., Neuzil, P., Kar, S., Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients With AF (PROTECT AF) clinical trial and the Continued Access Registry. Circulation 123 (2011), 417–424.
11. 11 Boersma, L.V., Schmidt, B., Betts, T.R., et al. Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION Registry. Eur Heart J 37 (2016), 2465–2474.
12. 12 Price, M.J., Reddy, V.Y., Valderrabano, M., et al. Bleeding outcomes after left atrial appendage closure compared with long-term warfarin: a pooled, patient level analysis of the WATCHMAN randomized trial experience. J Am Coll Cardiol Intv 8 (2015), 1925–1932.
13. 13 Alli, O., Doshi, S., Kar, S., et al. Quality of life assessment in the randomized PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients with Atrial Fibrillation) trial of patients at risk for stroke with nonvalvular atrial fibrillation. J Am Coll Cardiol 61 (2013), 1790–1798.
14. 14 Reddy, V.Y., Akehurst, R.L., Armstrong, S.O., et al. Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin. Europace 18 (2016), 979–986.
15. 15 Reddy, V.Y., Akehurst, R.L., Armstrong, S.O., Amorosi, S.L., Beard, S.M., Holmes, D.R. Jr., Time to cost effectiveness following stroke reduction strategies in AF: Warfarin versus NOACs versus LAA closure. J Am Coll Cardiol 66 (2015), 2728–2739.
16. 16 Gangireddy, S.R., Halperin, J.L., Fuster, V., Reddy, V.Y., Percutaneous left atrial appendage closure for stroke prevention in patients with atrial fibrillation: an assessment of net clinical benefit. Eur Heart J 33 (2012), 2700–2708.
17. 17 Tzikas, A., Shakir, S., Gafoor, S., et al. Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER cardiac plug. EuroIntervention 11 (2016), 1170–1179.
18. 18 Cappato, R., Calkins, H., Chen, S.A., et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 3 (2010), 32–38.
19. 19 Deshmukh, A., Patel, N.J., Pant, S., et al. In-hospital complications associated with catheter ablation of atrial fibrillation in the United States between 2000 and 2010: analysis of 93,801 procedures. Circulation 128 (2013), 2104–2112.
20. 20 Aminian, A., Lalmand, J., Tzikas, A., Budts, W., Benit, E., Kefer, J., Embolization of left atrial appendage closure devices: a systematic review of cases reported with the watchman device and the Amplatzer cardiac plug. Catheter Cardiovasc Interv 86 (2015), 128–135.
21. 21 Cappato, R., Calkins, H., Chen, S.A., et al. Prevalence and causes of fatal outcome in catheter ablation of atrial fibrillation. J Am Coll Cardiol 53 (2009), 1798–1803.
22. 22 Ledwoch, J., Franke, J., Gonzaga, M., et al. Left atrial appendage closure: first in man with the 4th generation Watchman device. Catheter Cardiovasc Interv 87 (2016), 787–794.